Hanbouch, Linda
Schaack, Béatrice
Kasri, Amal
Fontaine, Gaëlle
Gkanatsiou, Eleni
Brinkmalm, Gunnar
Camporesi, Elena
Portelius, Erik
Blennow, Kaj
Mourier, Gilles
Gilles, Nicolas
Millan, Mark J.
Marquer, Catherine
Zetterberg, Henrik
Boussicault, Lydie
Potier, Marie-Claude http://orcid.org/0000-0003-2462-7150
Funding for this research was provided by:
ANR (ANR-10-IAIHU-06)
ANR (ANR-18-COEN-0002 COEN4024)
Institut de Recherches Servier
Swedish Research Council (#2018-02532, #2017-00915)
European Research Council (#681712)
Swedish State Support for Clinical Research (#ALFGBG-720931)
Alzheimer Drug Discovery Foundation (#201809-2016862, #RDAPB-201809-2016615)
Swedish Alzheimer Foundation (#AF-742881)
Hjärnfonden, Sweden (#FO2017-0243)
ALF-agreement (#ALFGBG-715986)
EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236)
National Institute of Nursing Research (#1R01AG068398-01)
Alzheimer's Association (2021 Zenith Award)
Article History
Received: 22 April 2022
Accepted: 31 August 2022
First Online: 9 September 2022
Declarations
:
: Non applicable.
: Non applicable.
: HZ has served at scientific advisory boards for Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics and CogRx, has given lectures in symposia sponsored by Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, all unrelated to the work presented in this paper. MJM is a full-time employee of Servier Pharmaceuticals and has no other interest to declare.
: Non applicable.
: Non applicable.